Format

Send to

Choose Destination
Curr Opin Immunol. 2018 Apr;51:146-153. doi: 10.1016/j.coi.2018.03.013. Epub 2018 Mar 30.

Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Author information

1
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, United States.
2
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, United States. Electronic address: KRezvani@mdanderson.org.

Abstract

Recent advances in the field of cellular therapy have focused on autologous T cells engineered to express a chimeric antigen receptor (CAR) against tumor antigens. Remarkable responses have been observed in patients receiving autologous CD19-redirected T cells for the treatment of B-lymphoid malignancies. However, the generation of autologous products for each patient is logistically challenging and expensive. Extensive research efforts are ongoing to generate an off-the-shelf cellular product for the treatment of cancer patients. Natural killer (NK) cells are attractive contenders since they have potent anti-tumor activity, and their safety in the allogeneic setting expands the cell sources for NK cell therapy beyond an autologous one. In this review, we discuss advantages and limitations of NK cellular therapy, and novel genetic engineering strategies that may be applied to overcome some of the limitations. Next-generation engineered NK cells are showing great promise in the preclinical setting and it is likely that in the next few years CAR-engineered NK cells will be incorporated into the current armamentarium of cell-based cancer therapeutics.

PMID:
29605760
PMCID:
PMC6140331
[Available on 2019-04-01]
DOI:
10.1016/j.coi.2018.03.013

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center